{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:53:18Z","timestamp":1790092398353,"version":"4.0.1"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,1,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins. These come with the potential for undesirable side effects for triazoles or choosing between prolonged hospitalization or outpatient parenteral antimicrobial therapy in the case of echinocandins. Rezafungin offers an opportunity to manage extended treatment durations with shorter hospital stays and no extended parenteral access. Herein, we review the most recent published data pertaining to rezafungin including anti-fungal activity, pharmacokinetics, and clinical data relating to the treatment of invasive candidiasis. Given its prolonged half-life allowing for once-weekly dosing, rezafungin has the potential as an anti-fungal prophylactic agent in high-risk patients, and studies to examine this potential role are ongoing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00646-23","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T09:03:15Z","timestamp":1733994195000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["New Perspectives on Antimicrobial Agents: Rezafungin"],"prefix":"10.1128","volume":"69","author":[{"given":"Nicholas M.","family":"Forrister","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd P.","family":"McCarty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham","place":["Birmingham, USA"]},{"name":"Birmingham Veterans Affairs Medical Center","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-9931","authenticated-orcid":false,"given":"Peter G.","family":"Pappas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy827"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2021.03.007"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00478-08"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx448"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040262"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/520980"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00776-4"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw352"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02324-8"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01339-23"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.579"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.757"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1176"},{"key":"e_1_3_1_17_2","volume-title":"Performance standards for antifungal susceptibility testing of yeasts","author":"Procop G","year":"2022","unstructured":"Procop G, Dufresne P, Berkow E, Cullen S, Dingle T, Fuller J, Hanson K, Holliday N, Schuetz A, Verweij P, Wiederhold N, Zelazny A. 2022. Performance standards for antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute."},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00551-0"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01584-23"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.02.013"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlae042"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad079"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq081"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00758-17"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12640"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040192"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03255-14"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2019.05.008"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky153"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00029-17"},{"key":"e_1_3_1_31_2","unstructured":"Larkin E Long L Ghannoum M. 2017. Susceptibility of recent Candida auris isolates to the novel echinocandin CD101 and comparator antifungal agents. Vienna"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.175"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-20"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3396.3396"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00646-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00646-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T09:03:49Z","timestamp":1738314229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00646-23"}},"subtitle":[],"editor":[{"given":"Ryan K.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,31]]}},"alternative-id":["10.1128\/aac.00646-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00646-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"2024-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00646-23"}}